+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Mycosis Fungoides Therapeutics Market 2021-2025- Product Image

Global Mycosis Fungoides Therapeutics Market 2021-2025

  • ID: 5304739
  • Report
  • February 2021
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Helsinn Healthcare SA
  • Hikma Pharmaceuticals Plc
  • Horizon Therapeutics Plc
  • Kyowa Kirin Co. Ltd.
  • MORE
Global Mycosis Fungoides Therapeutics Market 2021-2025

The publisher has been monitoring the mycosis fungoides therapeutics market and it is poised to grow by $ 115.42 mn during 2021-2025, progressing at a CAGR of 5% during the forecast period. The report on mycosis fungoides therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the special drug designations, recent drug approvals and growing incidence of mycosis fungoides. In addition, special drug designations is anticipated to boost the growth of the market as well.

The mycosis fungoides therapeutics market analysis includes type segment and geographical landscapes.

The mycosis fungoides therapeutics market is segmented as below:

By Type
  • Small molecules
  • Biologics
By Geographical Landscapes
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the strong R&D of pipeline molecule as one of the prime reasons driving the mycosis fungoides therapeutics market growth during the next few years. Also, novel drug delivery system and increasing research funding will lead to sizable demand in the market.

The report on mycosis fungoides therapeutics market covers the following areas:
  • Mycosis fungoides therapeutics market sizing
  • Mycosis fungoides therapeutics market forecast
  • Mycosis fungoides therapeutics market industry analysis
The publisher robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading mycosis fungoides therapeutics market vendors that include Bristol-Myers Squibb Co., Eisai Co. Ltd., Helsinn Healthcare SA, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Pfizer Inc., Seagen Inc., and Takeda Pharmaceutical Co. Ltd. Also, the mycosis fungoides therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Helsinn Healthcare SA
  • Hikma Pharmaceuticals Plc
  • Horizon Therapeutics Plc
  • Kyowa Kirin Co. Ltd.
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Type
  • Market segments
  • Comparison by Type
  • Small molecules - Market size and forecast 2020-2025
  • Biologics - Market size and forecast 2020-2025
  • Market opportunity by Type
Customer landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Competitive scenario
  • Vendor landscape
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Helsinn Healthcare SA
  • Hikma Pharmaceuticals Plc
  • Horizon Therapeutics Plc
  • Kyowa Kirin Co. Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Seagen Inc.
  • Takeda Pharmaceutical Co. Ltd.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Type - Market share 2020-2025 (%)
  • Comparison by Type
  • Small molecules - Market size and forecast 2020-2025 ($ million)
  • Small molecules - Year-over-year growth 2020-2025 (%)
  • Biologics - Market size and forecast 2020-2025 ($ million)
  • Biologics - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Type
  • Customer landscape
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Bristol-Myers Squibb Co. - Overview
  • Bristol-Myers Squibb Co. - Product and service
  • Bristol-Myers Squibb Co. - Key offerings
  • Bristol-Myers Squibb Co. - Key customers
  • Bristol-Myers Squibb Co. - Segment focus
  • Eisai Co. Ltd. - Overview
  • Eisai Co. Ltd. - Business segments
  • Eisai Co. Ltd. - Key offerings
  • Eisai Co. Ltd. - Key customers
  • Eisai Co. Ltd. - Segment focus
  • Helsinn Healthcare SA - Overview
  • Helsinn Healthcare SA - Product and service
  • Helsinn Healthcare SA - Key offerings
  • Helsinn Healthcare SA - Key customers
  • Helsinn Healthcare SA - Segment focus
  • Hikma Pharmaceuticals Plc - Overview
  • Hikma Pharmaceuticals Plc - Business segments
  • Hikma Pharmaceuticals Plc - Key offerings
  • Hikma Pharmaceuticals Plc - Key customers
  • Hikma Pharmaceuticals Plc - Segment focus
  • Horizon Therapeutics Plc - Overview
  • Horizon Therapeutics Plc - Business segments
  • Horizon Therapeutics Plc - Key offerings
  • Horizon Therapeutics Plc - Key customers
  • Horizon Therapeutics Plc - Segment focus
  • Kyowa Kirin Co. Ltd. - Overview
  • Kyowa Kirin Co. Ltd. - Business segments
  • Kyowa Kirin Co. Ltd. - Key offerings
  • Kyowa Kirin Co. Ltd. - Key customers
  • Kyowa Kirin Co. Ltd. - Segment focus
  • Merck & Co. Inc. - Overview
  • Merck & Co. Inc. - Business segments
  • Merck & Co. Inc. - Key offerings
  • Merck & Co. Inc. - Key customers
  • Merck & Co. Inc. - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Seagen Inc. - Overview
  • Seagen Inc. - Business segments
  • Seagen Inc. - Key offerings
  • Seagen Inc. - Key customers
  • Seagen Inc. - Segment focus
  • Takeda Pharmaceutical Co. Ltd. - Overview
  • Takeda Pharmaceutical Co. Ltd. - Product and service
  • Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Takeda Pharmaceutical Co. Ltd. - Key customers
  • Takeda Pharmaceutical Co. Ltd. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Helsinn Healthcare SA
  • Hikma Pharmaceuticals Plc
  • Horizon Therapeutics Plc
  • Kyowa Kirin Co. Ltd.
  • MORE
The publisher recognizes the following companies as the key players in the global mycosis fungoides therapeutics market: Bristol-Myers Squibb Co., Eisai Co. Ltd., Helsinn Healthcare SA, Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Pfizer Inc., Seagen Inc., and Takeda Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is strong R&D of pipeline molecule.'

According to the report, one of the major drivers for this market is the special drug designations.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Helsinn Healthcare SA
  • Hikma Pharmaceuticals Plc
  • Horizon Therapeutics Plc
  • Kyowa Kirin Co. Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Seagen Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll